139 related articles for article (PubMed ID: 25393635)
21. Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study.
Bussey HI; Bussey M; Bussey-Smith KL; Frei CR
Pharmacotherapy; 2013 Nov; 33(11):1136-46. PubMed ID: 24038412
[TBL] [Abstract][Full Text] [Related]
22. How to Generate a More Accurate Laboratory-Based International Normalized Ratio: Solutions to Obtaining or Verifying the Mean Normal Prothrombin Time and International Sensitivity Index.
Favaloro EJ
Semin Thromb Hemost; 2019 Feb; 45(1):10-21. PubMed ID: 30134448
[TBL] [Abstract][Full Text] [Related]
23. [Bleeding secondary to vitamin K antagonist treatment: adaptation of the International Normalized Ratio (INR) determination during high hypertriglyceridemia].
Miot S; Marteau AT; Simard G; Lavigne C
Rev Med Interne; 2010 Jan; 31(1):60-2. PubMed ID: 19201067
[TBL] [Abstract][Full Text] [Related]
24. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism.
Veeger NJ; Piersma-Wichers M; Tijssen JG; Hillege HL; van der Meer J
Br J Haematol; 2005 Feb; 128(4):513-9. PubMed ID: 15686461
[TBL] [Abstract][Full Text] [Related]
25. Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients.
Mearns ES; Kohn CG; Song JS; Hawthorne J; Meng J; White CM; Raut MK; Schein JR; Coleman CI
Thromb Res; 2014 Aug; 134(2):310-9. PubMed ID: 24935672
[TBL] [Abstract][Full Text] [Related]
26. [The problem of hemorrhagic syndrome in its treatment with vitamin K antagonists (a review of literature)].
Vasil'ev SA; Vinogradov VL; Gemdzhian ÉG
Ter Arkh; 2012; 84(7):89-94. PubMed ID: 23045735
[TBL] [Abstract][Full Text] [Related]
27. Accuracy of a portable international normalized ratio monitor for patients receiving a low molecular weight heparin as a bridge pending full oral anticoagulant efficacy.
Meurin P; Tabet JY; Monchi M; Weber H; Fabre C; Gibier B; Renaud N; Driss AB
Thromb Res; 2010 Feb; 125(2):192-5. PubMed ID: 19942256
[TBL] [Abstract][Full Text] [Related]
28. Modelling of vitamin K half-life in patients treated with vitamin K antagonists before hip fracture surgery.
Combettes E; Mazoit JX; Benhamou D; Beloeil H
Anaesth Crit Care Pain Med; 2015 Oct; 34(5):295-9. PubMed ID: 26638965
[TBL] [Abstract][Full Text] [Related]
29. Vitamin K dosing to reverse warfarin based on INR, route of administration, and home warfarin dose in the acute/critical care setting.
Tsu LV; Dienes JE; Dager WE
Ann Pharmacother; 2012 Dec; 46(12):1617-26. PubMed ID: 23249867
[TBL] [Abstract][Full Text] [Related]
30. How safe is acetaminophen use in patients treated with vitamin K antagonists? A systematic review and meta-analysis.
Caldeira D; Costa J; Barra M; Pinto FJ; Ferreira JJ
Thromb Res; 2015 Jan; 135(1):58-61. PubMed ID: 25456003
[TBL] [Abstract][Full Text] [Related]
31. Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin.
Gerotziafas GT; Dupont C; Spyropoulos AC; Hatmi M; Samama MM; Kiskinis D; Elalamy I
Thromb Haemost; 2009 Jul; 102(1):42-8. PubMed ID: 19572066
[TBL] [Abstract][Full Text] [Related]
32. Poor correlation of supratherapeutic international normalised ratio and vitamin K-dependent procoagulant factor levels during warfarin therapy.
Sarode R; Rawal A; Lee R; Shen YM; Frenkel EP
Br J Haematol; 2006 Mar; 132(5):604-7. PubMed ID: 16445834
[TBL] [Abstract][Full Text] [Related]
33. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation.
Riess HB; Meier-Hellmann A; Motsch J; Elias M; Kursten FW; Dempfle CE
Thromb Res; 2007; 121(1):9-16. PubMed ID: 17407788
[TBL] [Abstract][Full Text] [Related]
34. MELD-XI: a rational approach to "sickest first" liver transplantation in cirrhotic patients requiring anticoagulant therapy.
Heuman DM; Mihas AA; Habib A; Gilles HS; Stravitz RT; Sanyal AJ; Fisher RA
Liver Transpl; 2007 Jan; 13(1):30-7. PubMed ID: 17154400
[TBL] [Abstract][Full Text] [Related]
35. [Effectiveness of anticoagulation with vitamin K antagonists in acute stroke patients with atrial fibrillation--Hungarian results].
Sas A; Csontos K; Lovász R; Valikovics A
Ideggyogy Sz; 2015 Jan; 68(1-2):47-51. PubMed ID: 25842916
[TBL] [Abstract][Full Text] [Related]
36. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease.
Tripodi A; Caldwell SH; Hoffman M; Trotter JF; Sanyal AJ
Aliment Pharmacol Ther; 2007 Jul; 26(2):141-8. PubMed ID: 17593061
[TBL] [Abstract][Full Text] [Related]
37. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR>10.
Gunther KE; Conway G; Leibach L; Crowther MA
Thromb Res; 2004; 113(3-4):205-9. PubMed ID: 15140584
[TBL] [Abstract][Full Text] [Related]
38. Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled, randomized, double-blind crossover study.
Iorio A; Basileo M; Marcucci M; Guercini F; Camilloni B; Paccamiccio E; Vecchioli M; Iorio AM
Arch Intern Med; 2010 Apr; 170(7):609-16. PubMed ID: 20386004
[TBL] [Abstract][Full Text] [Related]
39. Supratherapeutic international normalized ratio due to reduced vitamin K intake secondary to prolonged vomiting in a patient on warfarin.
Reaves AB; Clarke CJ; Tillman EM
Ann Pharmacother; 2013 Jun; 47(6):e28. PubMed ID: 23719786
[TBL] [Abstract][Full Text] [Related]
40. Fever as a risk factor for increased response to vitamin K antagonists: a review of the evidence and potential mechanisms.
Self TH; Oliphant CS; Reaves AB; Richardson AM; Sands CW
Thromb Res; 2015 Jan; 135(1):5-8. PubMed ID: 25456000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
